Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment

Dain, Lauren; Zhu, Guizhi

doi:10.1016/j.ijpharm.2023.122924

Cited by 7 publications

(5 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clock influences several important hallmarks and pathways in GBM. This implies that combining current emerging targeted therapies such as therapies targeting energy metabolism, angiogenesis, the PI3K/AKT/mTORC pathway 2 or immune therapies 63 , 64 with chronotherapy could improve their performance. Future research should therefore focus on exploring feasible methodologies to characterize the relationship between those GBM features and the clock in individual patients, and how to exploit it therapeutically.…”

Section: Discussionmentioning

confidence: 99%

“…Also, two studies found evidence for exosomes in mediating the interplay of the clock and tumour promoting inflammation, which makes them another interesting target 28 , 32 . As reviewed by Pinheiro et al 63 and Dain et al 64 there are different possibilities to reprogram immune cells such as cytokine therapy and immune checkpoint inhibitors. Approaches targeting IFNγ (Interferon gamma), TNFα, or the PD-1 (Programmed Cell Death 1)/PDL-1 (Programmed Cell Death Ligand 1) axis may provide excellent opportunities for combination with clock-based strategies, as those targets are controlled by the clock 63 .…”

Section: Impact Of the Clock On Gbm Tumour Promoting Inflammationmentioning

confidence: 99%

“…Approaches targeting IFNγ (Interferon gamma), TNFα, or the PD-1 (Programmed Cell Death 1)/PDL-1 (Programmed Cell Death Ligand 1) axis may provide excellent opportunities for combination with clock-based strategies, as those targets are controlled by the clock 63 . In addition, strategies targeting tumour antigens, namely vaccines, oncolytic viruses, and CAR-T-cells (Chimeric Antigen Receptor T-cells) may exploit differences in the clock and clock-controlled genes between GBM and healthy cells 63 , 64 .…”

Section: Impact Of the Clock On Gbm Tumour Promoting Inflammationmentioning

confidence: 99%

See 2 more Smart Citations

Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock

Nelson,

Relógio

2024

npj Precis. Onc.

View full text Add to dashboard Cite

Glioblastoma is one of the most lethal cancers with current therapeutic options lacking major successes. This underlines the necessity to understand glioblastoma biology on other levels and use these learnings for the development of new therapeutic concepts. Mounting evidence in the field of circadian medicine points to a tight interplay between disturbances of the circadian system and glioblastoma progression. The circadian clock, an internal biological mechanism governing numerous physiological processes across a 24-h cycle, also plays a pivotal role in regulationg key cellular functions, including DNA repair, cell cycle progression, and apoptosis. These processes are integral to tumour development and response to therapy. Disruptions in circadian rhythms can influence tumour growth, invasion, and response to treatment in glioblastoma patients. In this review, we explore the robust association between the circadian clock, and cancer hallmarks within the context of glioblastoma. We further discuss the impact of the circadian clock on eight cancer hallmarks shown previously to link the molecular clock to different cancers, and summarize the putative role of clock proteins in circadian rhythm disturbances and chronotherapy in glioblastoma. By unravelling the molecular mechanisms behind the intricate connections between the circadian clock and glioblastoma progression, researchers can pave the way for the identification of potential therapeutic targets, the development of innovative treatment strategies and personalized medicine approaches. In conclusion, this review underscores the significant influence of the circadian clock on the advancement and understanding of future therapies in glioblastoma, ultimately leading to enhanced outcomes for glioblastoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Impact Of the Clock On Gbm Tumour Promoting Inflammationmentioning

confidence: 99%

Section: Impact Of the Clock On Gbm Tumour Promoting Inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock

Nelson,

Relógio

2024

npj Precis. Onc.

View full text Add to dashboard Cite

show abstract

“…One of the most heavily researched brain cancers and most common is glioblastoma multiforme, an aggressive type of brain cancer that is formed from astrocytes ( Ray-Chaudhury and Ray, 2010 ). Treatment of these cancers is challenging because the tumor is very malignant and it is most common in older adults, who may not be able to tolerate aggressive chemotherapy ( Dain and Zhu, 2023 ). The current treatment plan for someone with glioblastoma cancer includes chemotherapy, radiation therapy, surgery to excise the tumor, experimental clinical trials, tumor treating fields (TTF) therapy, or palliative care, however survival rates are still very low ( mayoclinic, 2022a ).…”

Section: Current Nanomedicine Research and Therapeutics In Neurodegen...mentioning

confidence: 99%

Nanomedicine strategies for central nervous system (CNS) diseases

Nagri,

Rice,

Chen

2023

Front. Biomater. Sci.

View full text Add to dashboard Cite

The blood-brain barrier (BBB) is a crucial part of brain anatomy as it is a specialized, protective barrier that ensures proper nutrient transport to the brain, ultimately leading to regulating proper brain function. However, it presents a major challenge in delivering pharmaceuticals to treat central nervous system (CNS) diseases due to this selectivity. A variety of different vehicles have been designed to deliver drugs across this barrier to treat neurodegenerative diseases, greatly impacting the patient’s quality of life. The two main types of vehicles used to cross the BBB are polymers and liposomes, which both encapsulate pharmaceuticals to allow them to transcytose the cells of the BBB. For Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and glioblastoma brain cancer, there are a variety of different nanoparticle treatments in development that increase the bioavailability and targeting ability of existing drugs or new drug targets to decrease symptoms of these diseases. Through these systems, nanomedicine offers a new way to target specific tissues, especially for the CNS, and treat diseases without the systemic toxicity that often comes with medications used currently.

show abstract

“…There are no known risk factors for GBM, and it occurs without warning signs. Furthermore, its incidence increases with age, with white ethnicity being more commonly affected than black ethnicity, and males being more affected than females ( Newton et al, 2018 ; Grochans et al, 2022 ; Dain and Zhu, 2023 ). Considering the invasive nature of GBM and resistance to therapies, recurrence is observed after treatments ( Sareen et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment

Rahban,

Joushi,

Bashiri

et al. 2024

Front. Chem.

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a highly aggressive malignant primary tumor in the central nervous system. Despite extensive efforts in radiotherapy, chemotherapy, and neurosurgery, there remains an inadequate level of improvement in treatment outcomes. The development of large-scale genomic and proteomic analysis suggests that GBMs are characterized by transcriptional heterogeneity, which is responsible for therapy resistance. Hence, knowledge about the genetic and epigenetic heterogeneity of GBM is crucial for developing effective treatments for this aggressive form of brain cancer. Tyrosine kinases (TKs) can act as signal transducers, regulate important cellular processes like differentiation, proliferation, apoptosis and metabolism. Therefore, TK inhibitors (TKIs) have been developed to specifically target these kinases. TKIs are categorized into allosteric and non-allosteric inhibitors. Irreversible inhibitors form covalent bonds, which can lead to longer-lasting effects. However, this can also increase the risk of off-target effects and toxicity. The development of TKIs as therapeutics through computer-aided drug design (CADD) and bioinformatic techniques enhance the potential to improve patients’ survival rates. Therefore, the continued exploration of TKIs as drug targets is expected to lead to even more effective and specific therapeutics in the future.

show abstract

Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment

Cited by 7 publications

References 113 publications

Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock

Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock

Nanomedicine strategies for central nervous system (CNS) diseases

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment

Contact Info

Product

Resources

About